Anxiolytic effects of a galacto-oligosaccharides prebiotic in healthy females (18–25 years) with corresponding changes in gut bacterial composition

In this 2021 study, healthy female adults were assessed on mood and well-being after taking galacto-oligosaccharides (GOS) prebiotic supplements every day for 4 weeks. Stool samples were collected before and after the intervention to analyze their gut microbiota. This study focused on nutritional supplementation in participants transitioning between late adolescence and early adulthood since these supplements have the potential to offset health-related costs in later life. The results suggested that galacto-oligosaccharide (GOS) prebiotics may improve indices of pre-clinical anxiety. This was postulated based on the effect of GOS on trait anxiety, attentional bias, and bacterial abundance. These findings will contribute greatly to gut microbiota research. Having said that, with the current interest in this research area coming from scientists and community alike, additional human studies are warranted. [NPID: gut microbiota, galacto-oligosaccharides, prebiotics, supplementation, supplements, anxiety]

Year: 2021

Reference: Johnstone, N., Milesi, C., Burn, O., van den Bogert, B., Nauta, A., Hart, K., Sowden, P., Burnet, P., & Cohen Kadosh, K. (2021). Anxiolytic effects of a galacto-oligosaccharides prebiotic in healthy females (18-25 years) with corresponding changes in gut bacterial composition. Scientific reports, 11(1), 8302. https://doi.org/10.1038/s41598-021-87865-w

Related Studies

Probiotic lactobacillus plantarum 299v decreases kynurenine concentration and improves cognitive functions in patients with major depression: A double-blind, randomized, placebo controlled study

This 2019 double-blind, randomized, placebo-controlled study documented the affective and cognitive functions and biochemical parameters of 79 participants with major depressive disorder (MDD) to analyze the psychobiotic and immunomodulatory impact of the probiotic bacteria Lactobacillus Plantarum 299v (LP299v). Forty subjects were randomly selected to take a combination of SSRI antidepressant and the probiotic for 8 […]

Clinical and metabolic response to probiotic administration in patients with major depressive disorder: A randomized, double-blind, placebo-controlled trial

Akkasheh et al. (2016) designed this randomized, double-blind, placebo-controlled clinical trial involving 40 patients [aged 20-55, diagnosed with major depressive disorder (MDD) based on DSM-IV criteria] and randomly allocating them into 2 groups to receive either probiotics supplements or placebo (split on a 50:50 basis) for 8 weeks. The aim was to test what impact […]